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■ Abstract Dendritic cells (DCs) have several functions in innate and adaptive
immunity. In addition, there is increasing evidence that DCs in situ induce antigen-
specific unresponsiveness or tolerance in central lymphoid organs and in the periphery.
In the thymus DCs generate tolerance by deleting self-reactive T cells. In peripheral
lymphoid organs DCs also induce tolerance to antigens captured by receptors that me-
diate efficient uptake of proteins and dying cells. Uptake by these receptors leads to
the constitutive presentation of antigens on major histocompatibility complex (MHC)
class I and II products. In the steady state the targeting of DC antigen capture receptors
with low doses of antigens leads to deletion of the corresponding T cells and unre-
sponsiveness to antigenic rechallenge with strong adjuvants. In contrast, if a stimulus
for DC maturation is coadministered with the antigen, the mice develop immunity,
including interferon-γ -secreting effector T cells and memory T cells. There is also
new evidence that DCs can contribute to the expansion and differentiation of T cells
that regulate or suppress other immune T cells. One possibility is that distinct develop-
mental stages and subsets of DCs and T cells can account for the different pathways to
peripheral tolerance, such as deletion or suppression. We suggest that several clinical
situations, including autoimmunity and certain infectious diseases, can be influenced
by the antigen-specific tolerogenic role of DCs.
INTRODUCTION
The subject of this review, dendritic cells (DCs) in T cell tolerance, may seem
surprising. Prior research has emphasized the opposite outcome of DC function:
strong innate and adaptive immunity to infections and other antigens in vivo (1–6).
However, these two apparently incompatible functions can be reconciled in a
number of ways. For example, the induction of tolerance by the deletion of naive
∗Abbreviations: DCs, dendritic cells; MMR, macrophage mannose receptor; HEL, hen egg
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peripheral T cells takes place in the steady state, whereas the initiation of immunity
occurs in the context of signals associated with infection and inflammation.
Infection stimulates DCs to coordinate many protective functions by immune
cells, and these have been documented in vivo. Microbial products trigger DCs
to produce large amounts of immune enhancing cytokines, such as interleukin-12
(IL-12) (7) and interferon-α (IFN-α) (8). DCs exposed to inflammatory cytokines
rapidly activate other innate protective cells such as natural killer (NK) (9) and
NKT cells (10). Mature DCs initiate or prime T cell responses (11, 12), including
protective immunity to infection (13) and tumors (14). Furthermore DCs are able
to rapidly polarize the immune response to either Th1 or Th2 types (15–17) and
to improve T cell memory (18, 19).
These functions in the control of innate and adaptive immunity require that
DCs undergo terminal differentiation or maturation. Maturation is induced by nu-
merous agents including microbial infection. In vivo, two major receptor families
play prominent roles: toll-like receptors (20–22) and tumor necrosis factor (TNF)-
receptors, especially CD40 (23–25). Likewise in vitro, DCs are matured by expo-
sure to lipopolysaccharide (26), inflammatory cytokines including TNFα (27, 28),
and CD40 ligation (29–31). Maturation results in several phenotypic changes that
are linked to an enhanced ability to process antigens and activate T cells. These phe-
notypic changes include increased production of MHC-peptide complexes (32),
increased expression of T cell binding and costimulatory molecules (29, 33), and
de novo production of growth factors such as IL-2 (34) and thiols (35), chemokines
(36), and cytokines (37). Therefore for DCs to serve as “nature’s adjuvants” for
immunity (11), they need to mature in response to stimuli inherent to the infection,
vaccine, or other settings such as transplantation and contact allergy.
The expanding literature on the capacity of DCs to induce T cell tolerance in
vivo originated with experiments on DCs that are not fully mature, especially those
found in peripheral lymphoid tissues in the steady state. It has become possible
to deliver defined antigens to specific populations of DCs in the absence of mat-
uration stimuli (23–25) without subjecting the DCs to isolation and manipulation
ex vivo, procedures that can mature the cells (11, 38, 39). The targeting of anti-
gens to DCs in vivo involves specific uptake receptors that deliver the antigens to
processing compartments for the formation of class I and II MHC-peptide com-
plexes. Importantly, DCs within lymphoid tissues are able to form MHC-peptide
complexes in the steady state without the administration of maturation stimuli.
Naive T cells, after recognizing their ligands on these DCs, divide repeatedly
but are then deleted, and the animal becomes tolerant. In contrast, if maturation
stimuli are coadministered with antigen, immunity develops. Another strategy to
dampen immune function is to prepare DCs ex vivo and expose them to antigen
but not to full-maturation stimuli. These DCs, when reinfused, downregulate im-
munity (40–43) and can induce regulatory T cells (see below). In contrast, mature
DCs are immunogenic in animals (32, 44) and humans (16, 45–48). However, the
physiological counterpart of these ex vivo–derived human DCs and the induc-
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TABLE 1 T cell tolerance: some questions
Experimentally, high doses of preprocessed peptides are used to tolerize animals. Can T cell
tolerance be induced to low levels of intact proteins including self and environmental
antigens?
During dendritic cell maturation a mixture of microbial, self-, and environmental antigens are
captured simultaneously. How is the initiation of autoimmunity and chronic reactivity to these
antigens avoided?
Clinically, suppression of the immune response utilizes antigen-nonspecific inhibitors.
Can antigen-specific tolerance be induced to transplants, allergens, and autoantigens?
There are many mechanisms for tolerance: anergy, deletion, and regulatory and suppressor
T cells. How are these mechanisms induced and controlled in vivo?
This review on DCs in tolerance deals with four challenging questions (Table 1).
First, is it possible to use low doses of intact antigens to silence the immune system
in vivo? It seems vital that the immune system remains tolerant to intact proteins,
both self and environmental, that are present in small amounts. Yet experimentally,
it has been necessary to use high doses of soluble proteins and usually preprocessed
peptides to induce tolerance (49–53). We review how the targeting of antigens to
appropriate DCs induces tolerance in vivo with low doses of antigen and thereby
more effectively controls the tolerogenic potential of the immune system. Second,
when DCs are maturing in response to an infection, how do they avoid the risk
of inducing autoimmunity to self-antigens and chronic reactivity to environmen-
tal proteins? It is to be expected that DCs during infection will present a mix of
antigens, not just those from the microbe but also antigens from dying self-tissues
and from proteins in the airway or intestine. We consider the evidence that DCs
may solve this dilemma by ensuring that tolerance develops to those harmless
antigens that will subsequently be processed during infection. Third, can antigen-
specific tolerance be induced in clinical settings, such as transplantation, allergy,
and autoimmunity? Current treatments employ antigen-nonspecific immune sup-
pressants that globally block lymphocyte costimulation and cytokine production.
DC-based tolerance offers the potential to manipulate the immune response in a
more antigen-specific manner. Fourth, how are the many known mechanisms for
T cell tolerance [reviewed elsewhere (54–57)] engaged and controlled in the in-
tact animal and patient? We review examples in which antigen presentation via
DCs leads to the control of specific tolerance mechanisms in vivo. The control of
tolerance is in a sense analogous to the control of immunity (58) in that antigens,
lymphocytes, and DCs need to operate in concert.
ROLE OF DENDRITIC CELLS IN CENTRAL TOLERANCE
A Role for Dendritic Cells in T Cell Deletion
The experiments of Medawer and colleagues demonstrated that the developing im-
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Experimentally, tolerance also means antigen-specific nonresponsiveness to a chal-
lenge with antigen delivered with a strong adjuvant. They injected mice in utero
with allogeneic spleen cells and induced specific transplantation tolerance (59).
An early tissue culture model paralleled these experiments (60). Allogeneic DCs
from spleen were added to fetal thymic organ cultures. The T cells that developed
in these cultures were specifically unresponsive when rechallenged with the cells
from the DC donor but were normally responsive to third-party allogeneic DCs. It
was subsequently shown that DCs applied to such organ cultures enter the thymi
and take up residence in their normal location, the thymic medulla (61). Thus,
allogeneic DCs can redefine “self” if they are able to access the thymus prior to
development of the T cell repertoire.
The function of DCs in central tolerance was taken into the realm of self-
antigens with C5, the fifth component of serum complement proteins. DCs pulsed
with low doses of C5 in culture deleted C5 reactive transgenic thymocytes in vitro
(62). Thymic macrophages lacked this capacity, but medullary epithelium was
active. In subsequent experiments the cell types presenting endogenous C5 in vivo
were identified. Different cells were isolated from C5-sufficient mice and tested for
their capacity to negatively select developing, C5-reactive, T cell receptor (TCR)-
transgenic T cells in culture. Both DCs and epithelial cells induced deletional
tolerance (63).
A less invasive approach to establishing DC function in central tolerance used
the CD11c promoter to express the I-E gene selectively in the thymic DCs of
C57BL/6 mice (64). This led to efficient negative selection of I-E reactive, Vβ5+
and Vβ11+, CD4+ T cells. In contrast to their function in negative selection, DCs
are neither active nor required for positive selection, which can be fully supported
by cortical epithelial cells (65–67).
Some Aspects of Mechanism of Dendritic Cell Function
in the Thymus
It would be valuable to learn to manipulate central tolerance at the level of thymic
DCs. However, experiments that selectively target antigens to thymic DCs, as we
describe for peripheral lymphoid organs below, have yet to be carried out. It also
is difficult to selectively engraft DCs into the thymus in vivo. For the most part,
precursors in a total-marrow inoculum have been used (68). There is new evidence
that thymic DCs themselves, not splenic DCs, home in vivo to the thymus via the
intravenous route and that this can be used to prolong graft survival in a donor-
specific way (69).
Two features of thymic DC function are currently apparent. First, the DCs are
localized almost exclusively to the medulla (70, 71), which seems to be a major
site of deletion of positively selected thymocytes (72, 73). Second, thymic DCs are
presumably comparable to other sources of DCs in being efficient in antigen capture
and processing. This would lead to the production of MHC-peptide complexes,
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Thymic medullary epithelium also expresses high levels of antigen-presenting
MHC products and should play a significant role in central tolerance, especially
for many self-antigens produced by the epithelium (74, 75).
THE NEED FOR EFFICIENT MECHANISMS
OF PERIPHERAL TOLERANCE
Central tolerance is efficient, but it is also incomplete. Self-reactive T cells, espe-
cially those with a lower affinity for self-antigens, can escape negative selection
(76). Other self-proteins, for which tolerance is required, may not access the thy-
mus. This is also the case with most harmless environmental proteins, to which
chronic immune reactivity must not develop. Peripheral tolerance (77, 78) is there-
fore necessary to supplement central tolerance. Efficient tolerance mechanisms are
especially important at sites of infection, where maturing DCs process and present
both self- and nonself-antigens. It has been known for some time that maturation is
a control point for initiating immunity (11, 38, 39), but the concept that this carries
substantial risks emerged when DCs were found to process antigens from dying
cells. Examples included infected cells (79–81), tumor cells (82, 83), and allo-
geneic cells (84, 85). For MHC class I, presentation of influenza peptides occurred
with just one dying influenza-infected monocyte per 10 DCs (79). Likewise, DCs
processed trace Epstein-Barr Virus (EBV) latency antigens from apoptotic and
necrotic transformed cell lines and then expanded both CD4+ and CD8+ EBV-
specific T cells (86, 87). With dying allogeneic cells, it was possible to monitor
the formation of MHC class II–peptide complexes directly with a specific anti-
body. When this was done, the formation of MHC-peptide complexes was>1000
times more efficient when DCs were given a protein as part of a dying cell rel-
ative to preprocessed peptide (84). In all of these examples, a foreign antigen is
presented, but the entire cell is processed, and therefore the DCs should be loaded
with MHC-self- and MHC-nonself-peptide complexes.
An additional literature shows that DCs also capture soluble proteins in the
steady state, in the absence of overt infection or adjuvants (88–91). In these early
experiments, which used several different routes of antigen injection, DCs were
isolated from the animals and added to activated antigen-specific T cells in culture;
the T cells then proliferated without further addition of antigen. More recent ex-
periments directly visualized in vivo DC uptake of soluble proteins administered
into the airway (92) and of self-components from intestinal and gastric epithelial
cells (93, 94). Therefore DCs are continually capturing and presenting self- and
harmless environmental proteins.
The endocytic and processing activities of DCs create a conundrum with respect
to their function in innate and adaptive resistance to infection. If maturing DCs
simultaneously capture a mixture of microbial antigens, self tissues, and harmless
environmental proteins, how is the response limited to the microbe? To resolve
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in the steady state but use their antigen-handling capacities to play a major role in
peripheral tolerance (95, 96).
LOW DOSES OF SOLUBLE ANTIGENS INDUCE PERIPHERAL
TOLERANCE WHEN TARGETED TO DENDRITIC CELLS IN
THE STEADY STATE
The MMR and DEC-205, Two Multilectin Endocytic Receptors
DCs express several adsorptive endocytosis receptors, which could be used to tar-
get antigens for processing and presentation in vivo. For example, DCs express the
MMR (macrophage mannose receptor) (CD206) and DEC-205 (CD205), a pair of
homologous, large type-I membrane proteins. The MMR (97, 98) and DEC-205
(99, 100) have similar domain structures with an external cysteine-rich domain
followed by a fibronectin II domain and several contiguous C-type lectin domains,
10 in the case of DEC-205 and 8 in the case of the MMR. The cytosolic domain of
each receptor has a tyrosine-based coated pit localization sequence. These recep-
tors localize to coated pits and are taken up into coated vesicles and endosomes
(100, 101).
The ligands for the MMR include mannosyl and fucosyl residues for the C-type
lectin domains and select sulfated sugars for the terminal cysteine-rich domain
(102). Endogenous self-ligands for the MMR include lysosomal hydrolases and
certain collagen-like peptides in serum (103). Natural ligands for DEC-205 are not
yet known. Nevertheless, antibodies to DEC-205 can be used as surrogate antigens
and for antigen targeting to DCs (23, 24, 100, 104).
Although both MMR and DEC-205 can be expressed by DCs, their distribution
in vivo is distinct. Whereas the MMR is prominent on human monocyte–derived
DCs in culture (105), this receptor has yet to be detected on DCs in the T cell areas of
lymphoid organs in either mice (106) or humans (107). Instead, the MMR is found
on the endothelium lining lymphatic sinuses and in macrophages of splenic red pulp
and lymph node. Therefore the MMR may not provide a way to selectively target
ligands to DCs in the steady state. In contrast, DEC-205 is expressed abundantly on
T cell area DCs, as first shown by the development of the NLDC-145 monoclonal
antibody (108), and it does provide a means to target antigens to DCs in vivo (see
below).
In terms of antigen-presenting function, the only study to simultaneously com-
pare the function of the MMR and DEC-205 involved cultured mouse bone marrow
DCs, and it yielded surprising results. Rabbit antibodies to DEC-205 were pre-
sented 30–100 times more efficiently than antibodies to MMR, even though both
antibodies bound comparably to the cell surface and entered the endocytic system
(104). The MMR recycled quickly through cells via early endosomes, as is the
case for many adsorptive endocytosis receptors. In contrast, DEC-205 localized
both to early endosomes and MHC class II+ late endosomes and lysosomes. An
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target MHC II compartments. This was shown in L cells transfected with a fusion
receptor formed by the external region of the CD16 Fcγ receptor and the cytosolic
tail of DEC-205. The targeting to MHC II compartments led to a marked increase
in the efficiency of antigen presentation on MHC class II.
In addition to improved MHC class II presentation, ligands for DEC-205 are
processed via the exogenous pathway to MHC class I in a transporters for antigenic
peptides (TAP)-dependent manner (24). Although the cell biology of the exogenous
pathway has not been worked out, it has been proposed that a transporter in the
DC endocytic system allows macromolecules to enter the cytoplasm. According
to this model, such antigens would be processed by proteasomes in the cytoplasm
and transported into the endoplasmic reticulum via TAPs (109).
Finally, DEC-205 is an excellent antigen delivery vehicle because monoclonal
antibodies to this receptor efficiently target DCs in vivo. When the purified anti-
DEC-205 IgG is injected subcutaneously, most CD11c+ DCs in the draining
lymph node take up the antibody (23). Uptake is not detected in lymphocytes
or macrophages, either in cell suspension or in tissue sections. In conclusion,
DEC-205 is a valuable antigen-targeting receptor on DCs because antigens de-
livered to this receptor are processed for presentation on both MHC class I and II
and because targeting is specific and efficient.
Other Receptors for Endocytosis on Dendritic Cells
DCs express several other molecules capable of mediating adsorptive uptake. Many
of these, in contrast to the MMR and DEC-205, are type II transmembrane proteins
with a single external C-type lectin domain. Each of these lectins mediates uptake of
its corresponding monoclonal antibody and, in some cases, presentation to mouse
Ig-specific T cells. However, these monolectins have been studied primarily in
human cell cultures and there is no information concerning antigen presentation
in vivo, including the exogenous pathway to MHC class I. This is of some interest
because the lectins are expressed by subsets of DCs. For example, Langerin or
CD207 is expressed in Langerhans cells (110), the asialoglycoprotein receptor
type 1 (111) and DC-SIGN or CD209 (112) in monocyte derived DCs, and the
BDCA-2 molecule in plasmacytoid DCs (113).
Additional endocytic receptors are shared with other cells. Nevertheless, these
receptors are distinctive because uptake into DCs leads to presentation by the
exogenous pathway to MHC class I. Some examples include the FcγR for immune
complexes (114, 114a,b,c) and theαVβ5 andαVβ3 integrins for dying cells (79).
In summary, there are many potential ways to enhance the efficiency of antigen
presentation through receptor-mediated uptake, but for most of these, there is little
in vivo validation at this time.
Delivery of Peptides Engineered into the Anti-DEC-205 Antibody
To test the idea that antibodies to DEC-205 efficiently target antigens to DCs
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for a hen egg lysozyme (HEL) peptide presented on I-Ak molecules (23). The
constant regions of the rat heavy chain also were replaced with mouse C regions
carrying mutations to block binding to Fcγ receptors. Submicrogram amounts
of the engineered antibody were then injected into mice that were adoptively
transferred with HEL-specific TCR transgenic T cells. In spite of the low doses
of antigen injected (<1 µg of Ig, corresponding to<20 ng of peptide prior to
processing), efficient presentation took place on DCs in situ. All of the transgenic
CD4+ T cells underwent at least four to seven divisions, but then they were almost
entirely deleted (23). To establish that the animal was tolerized to the peptide
delivered by anti-DEC-205, the mice were rechallenged with peptide in complete
Freund’s adjuvant. Such mice failed to respond, indicating that the adoptively
transferred T cells had been tolerized by selective presentation of antigens on DCs
in the steady state. The opposite outcome developed if parallel groups of animals
were given anti-DEC-205/HEL antibody plus a DC maturation stimulus, agonistic
CD40 antibody. Under DC maturation conditions, the transgenic CD4+ T cells
produced large amounts of IFN-γ and were not deleted (23).
These results indicate that low doses of intact soluble proteins, when targeted
to DCs in the steady state, are successfully processed and presented, leading to
deletional tolerance in the corresponding antigen-reactive T cells. In contrast, im-
munity ensues if anti-CD40 is also given to the antigen-targeted mice. It is formally
possible that these two distinct outcomes represent the function of separate lin-
eages of immunogenic and tolerogenic DCs. However, we favor the interpretation
that the same DCs function in immunity and tolerance depending on their state of
maturation.
Delivery of Proteins Conjugated to the Anti-DEC-205 Antibody
A related DC-targeting approach involves the chemical conjugation of whole pro-
teins to the anti-DEC-205 antibody (24). Following injection of∼100 nanograms
of ovalbumin conjugated to anti-DEC-205, an average of about 105 ovalbumin
molecules were selectively captured by each CD11c+ lymph node DC. Plateau
levels of ovalbumin were evident in the DCs for 12–48 h after subcutaneous injec-
tion. As shown for the engineered antibody (23), anti-DEC targeting with chem-
ical conjugates did not perturb the DCs, even in the presence of antigen-reactive
transgenic T cells (24). In contrast, simultaneous administration of anti-CD40
led to large increases in expression of CD40, CD80, CD86, and MHC class II
(23, 24).
One valuable feature of ovalbumin as a model protein is that CD8+MHC class
I–restricted TCR transgenic OT-I cells are available. Indeed, DEC-205 mediated
ovalbumin presentation on MHC class I through a TAP-dependent pathway. As
in the case with CD4+ TCR transgenic T cells above, CD8+ T cells were first
driven into multiple cell cycles. Then the CD8+ T cells were also deleted over
9–14 days, and the animals became tolerant to immunization with ovalbumin in
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if the animals were given an agonistic anti-CD40 antibody together with the
anti-DEC-205:ovalbumin conjugate (24).
DEC-205 is the first DC receptor to be targeted in vivo with defined antigens.
The studies indicate that DCs in lymph node constitutively present antigens on
both MHC class I and II products, and that receptor-mediated pathways allow
very small amounts of protein to be processed successfully. T cells that recognize
antigens targeted to DCs in the steady state proliferate actively but then disappear,
and the animals become tolerant. All of the TCR transgenic T cells that have
been evaluated for tolerance have a high affinity for the antigen in question. In
this setting DCs function efficiently to maintain peripheral tolerance in the steady
state.
CELL-ASSOCIATED ANTIGENS TARGETED TO DENDRITIC
CELLS IN THE STEADY STATE ALSO INDUCE DELETIONAL
TOLERANCE
Delivery of Pancreatic Islet β Cell Antigens to Dendritic Cells
Several laboratories have produced transgenic mice using the rat insulin pro-
moter to direct antigen expression in pancreatic isletβ cells. In each caseβ
cell–associated antigens were presented to T cells (both CD8+ and CD4+) in
the steady state. However, antigen presentation was not mediated by the isletβ
cells but by bone marrow–derived cells in the draining pancreatic lymph nodes.
For example, when MHC class I restricted ovalbumin-specific T cells were adop-
tively transferred into mice expressing ovalbumin as part of the external domain of
the transferrin receptor, T cell proliferation was found in the draining pancreatic
lymph nodes (115, 116). In this particular transgenic line, the rat insulin promoter
also drove expression of ovalbumin in renal epithelium. Accordingly, presentation
to OT-I T cells took place in renal lymph nodes as well. To prove antigen presenta-
tion by bone marrow–derived cells, bone marrow chimeras were constructed such
that only bone marrow–derived cells could present the relevant peptide (theβ cells
expressed mutant H-2Kb MHC class I molecules that could not present peptide
to OT-I T cells). Only mice transferred with the restricting H-2Kb bone marrow
demonstrated T cell proliferation in the lymph nodes, establishing that ovalbumin
antigen moved from theβ cell to bone marrow–derived antigen-presenting cells
in the lymph node. Similar experiments have been performed using an influenza
hemagglutin peptide expressed inβ cells and presented to CD8+ T cells (117) and
an islet cell autoantigen in NOD diabetes-prone mice presented to CD4+ T cells
(118).
DCs have been identified as the cells responsible for the presentation of islet-
derived antigens. At first, the evidence was difficult to obtain. If DCs were isolated
from pancreatic lymph nodes where presentation was taking place, it was difficult
to detect stimulation of antigen-specific T cells in culture. An in vivo experiment
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relevant levels of MHC-peptide in culture.β2-microglobulin-negative mice (MHC
class I deficient) were given bone marrow from donors expressing the requisiteβ2-
microglobulin under the control of the CD11c promoter (119). In mice, it is known
that high-level CD11c expression occurs primarily if not exclusively in DCs (70).
Also, selection of cells from lymphoid tissues on the basis of CD11c expression
yields highly enriched populations of CD11c+ DCs and CD11c− non-DCs (120).
The H-2Kb-expressing DCs were found to direct presentation of ovalbumin in
pancreatic lymph nodes in vivo, even though the ovalbumin was expressed in
MHC class I–negativeβ cells.
Confirmation that DCs in lymph nodes present cell-associated antigens has also
been obtained using RIP transgenic mice expressing a herpes virus glycoprotein
in β cells. In a sensitive bioassay, CD11c+ pancreatic lymph node DCs from these
mice presented antigen to a virus-specific, CD8+ T-T hybridoma (121). When
DCs from these mice were fractionated into CD8+ DCs and CD8− DCs, only the
CD8+ fraction was active in antigen presentation. In contrast, when presentation
was studied in another system (a pancreatic isletβ autoantigen for CD4+ T cells),
the CD11b high (also CD8−) DC subset presented antigen (118). The reason for
this apparent disparity is not yet evident.
Together these studies show that several different antigens in pancreaticβ cells
can be presented by DCs in the draining nodes. The presentation is constitutive; that
is, whenever one injects specific T cells, they begin to proliferate in the draining
lymph nodes. The mechanism for antigen transfer from nonhematopoietic cells to
the DCs has not been defined. In the NOD system above, transfer of antigen to
DCs was increased by streptozotocin, which killsβ cells. This implies that dying
cells are the vehicle for antigen transfer from the islet to lymph node DCs (118)
and that in the steady state DCs capture cells that die during the normal process of
β cell turnover.
Capture of Cell-Associated Antigens by Dendritic Cells
in Other Peripheral Tissues
A subset of DCs with prominent, DNA-positive, inclusion bodies (Feulgen stain)
was first found in mesenteric afferent lymph (122). These inclusion bodies are
apoptotic bodies, as defined by the TUNEL staining method. The inclusions are
derived from intestinal epithelial cells, because some can be stained with an anti-
body to an epithelial form of keratin (93). In addition, large numbers of DCs in the
draining mesenteric lymph node, but not in other lymph nodes, have high levels of
an esterase isoform found in the intestine but not in DCs or macrophages. Within
the lamina propria, DCs marked by the OX62 mucosal integrin and expression
of MHC class II also have TUNEL-positive inclusions and nonspecific esterase.
Taken together, these experiments indicate that DCs in mesenteric lymph mediate
a substantial flux of dying intestinal epithelial cells to the draining lymph node in
the steady state. Interestingly, a subset of CD4− Cs is responsible. This subset
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takes up dying cells (see below). However, it is not known whether the lymph DCs
that migrate to the nodes become resident in the T cell area and present the antigen
or if the migratory DCs die quickly and are then processed by other lymph node
DCs, the latter being particularly efficient at forming MHC-peptide complexes
(84).
Capture and processing of cell-associated antigen in the periphery has been
documented using monoclonal antibodies to an authentic autoantigen, the proton
pump ATPase of the gastric parietal cell (94). This autoantigen was found in
CD11c+ cells beneath the gastric epithelium and in the draining lymph node.
Furthermore, the number of ATPase-containing DCs increased markedly during
gastritis relative to the steady state. The antigen was processed to form MHC-
peptide complexes in vivo because CD11c+ DCs could be isolated (exclusively
from the gastric lymph node), treated with chloroquine to block antigen processing
upon isolation, and shown to stimulate ATPase-specific T cells (94).
Immune Tolerance Induced by Dendritic Cells Presenting
Antigens from Dying Cells
The functional consequences of the presentation of dying cells by DCs were studied
with ovalbumin as a surrogate cell-associated antigen (25). In this experimental
system, antigen is introduced into the dying cells by osmotic shock (123). Dead
cells are then injected into mice, whereupon the cells are taken up by recipient
DCs (124). Uptake is remarkably selective for the CD8+ subset of splenic DCs,
one of the clearest differences in the functions of the CD8+ and CD8− subsets
(124, 124a). These subsets may differ more in their endocytic receptors, rather
than their ability to present cell-associated antigen by a TAP-dependent pathway.
CD8+ DCs selectively capture dying cells, but both subsets can capture virus like
particles (125) and soluble proteins (K. Liu, B. Bonifaz, K. Inaba & R.M. Steinman,
unpublished observations).
As in the cross presentation of isletβ cells discussed above, ovalbumin-specific
T cells transferred into mice receiving ovalbumin-loaded dead cells at first pro-
liferated actively (25). Again, submicrogram amounts of ovalbumin within the
injected cells were sufficient to induce active proliferation of large numbers of
CD8+ T cells (25). However, most of the antigen-specific T cells were deleted
from the blood, spleen, and lymph nodes after one week. Furthermore, the animals
became tolerant to immunization with ovalbumin in complete Freund’s adjuvant.
Interestingly, if the T cells were removed from mice prior to deletion and then
stimulated in culture, they exhibited changes consistent with the development of
immunity rather than tolerance, that is, upregulation of CD25 IL-2 receptors and
downregulation of CD62L lymph node homing receptors. Although this type of
response is often designated as cross-priming, the priming is observed in vitro,
whereas tolerance can be the outcome in vivo. Therefore to observe peripheral
tolerance induced by DCs in situ, it is important not to perturb the DCs or the
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The essential role of DCs in the presentation of cell-associated antigens has
recently been demonstrated by selective deletion of these cells in mice (126). The
CD11c promoter was used to create transgenic mice expressing the human receptor
for diptheria toxin on DCs. When a single dose of the toxin was administered
to these mice, CD11c+ DCs were selectively deleted for 1–2 days. During this
interval the DC-depleted mice could not present ovalbumin associated with dying
splenocytes (126).
Together these new experiments indicate that antigens can be transferred from
many types of donor cells (endocrine cells, epithelial cells, leukocytes) to DCs
constitutively in the steady state and that the outcome of antigen presentation is
the deletion of naive peripheral T cells and systemic antigen-specific tolerance.
This pathway may also be capable of deleting memory T cells (127).
DENDRITIC CELLS AND THE CONTROL OF SUPPRESSOR
AND REGULATORY T CELLS
T Cells that Regulate or Suppress Other Effector T Cells
Regulatory (Tr1) and suppressor (Ts) T cells block the function of other effector
CD4+ and CD8+ T cells (54, 128–131). As a result, immune tolerance is achieved.
It is not yet clear if Tr1 and Ts are distinct in their mechanism of action, but both are
unable to respond to anti-CD3 stimulation unless one adds IL-2 and possibly ad-
ditional growth factors. Methods are now available to clone both Tr1 and Ts (132).
The term Ts is often used for CD4+ CD25+ cells that are produced in the thymus,
with selection taking place on the cortical epithelium (131, 133, 134). The term
Tr1 is often used for cells that are generated from peripheral CD25− precursors
and have the potential to produce IL-10 and/or TGFβ (131, 132). Both Ts and Tr1
suppress immune responses in vivo; for example Ts suppress autoimmune models
of gastritis, thyroiditis, diabetes, and oopheritis (128), and Tr1 suppresses allore-
activity in the setting of graft versus host disease (135, 136) and blocks immune
function in certain infections (137, 138). Therefore it is possible that there are two
forms of actively tolerogenic T cells that are distinct in their origin and targets. It
will be valuable to determine the contribution of DCs, or specific DC subsets and
stages of maturation, to the formation and function of these T cells in vivo.
Influence of Dendritic Cells on Regulatory T Cell Formation
When DCs are produced from human blood monocytes by culture in IL-4 and GM-
CSF, they are weak initiators of immunity. The physiologic counterpart of these
in vitro–produced immature DCs is not known, but it has been hypothesized that
they correspond to monocytes beginning to differentiate into DCs during transit
from tissue spaces into afferent lymphatics (139, 140). When ex vivo monocyte-
derived DCs undergo maturation through toll-like receptor stimuli, CD40L, or
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and effector cell development (27, 28). Immature DCs, however, are not necessar-
ily inactive. Allogeneic T cells, when cultured with immature DCs, can become
refractory to antigenic restimulation, even by mature DCs (141). The T cells also
can inhibit other T cells from responding to mature DCs in vitro. This regulatory
function requires cell contact and is also partially blocked by anti-IL-10 antibodies,
leading to the interpretation that Tr1 can be induced by monocyte-derived immature
DCs (141). It has been proposed that DC expression of the ILT3 immunoglobulin-
like transcript also contributes to the induction of Tr/Ts (141a).
Similar populations of immature and mature monocyte-derived DCs pulsed
with an influenza matrix peptide have been used to examine the CD8+ immune
response in healthy human volunteers primed by natural exposure to influenza.
When the DCs were matured with inflammatory cytokines and injected back into
the monocyte donor, they induced a clear immune response. The number of effector
CD8+ T cells in blood expanded (47), and memory T cells became responsive to
lower doses of matrix peptide (18). In contrast, 1 week after injection with matrix
peptide–pulsed immature DCs, the two volunteers showed a marked decrease in
their memory IFN-γ response and a parallel increase in matrix-peptide responsive,
IL-10 producing cells (41). With time (months), the IL-10 producers waned and
the IFN-γ producers reappeared. However, when CD8+ T cells from the 1-week
immune samples were mixed with preimmunization or recovery samples, the IFN-
γ response was nullified (142). All the effects were specific for flu matrix peptide;
that is, there were no IL-10 producing cells for EBV and cytomegalovirus (CMV)
peptides, and the flu peptide did not suppress EBV and CMV responses. These
experiments were interpreted to mean that DCs produced from monocytes with
GM-CSF and IL-4 expand specific Tr1 cells when injected in vivo.
DCs isolated from mouse lungs after intranasal administration of ovalbumin
(143), or from mouse spleen after administration of aggregated Ig (42), produce
IL-10, as is the case for DCs in gut mucosal–associated lymphoid tissue (144) and
lipopolysaccharide-stimulated monocyte-derived DCs from human blood (145–
147). IL-10 enhances the formation of mouse (148) and human (132, 149) Tr1.
The DCs isolated from lungs following intranasal ovalbumin caused cultured T
cells to produce IL-10 (as well as IL-4) (143). This work has recently been extended
to DCs and antigen-specific Treg in vivo, with evidence for a critical role for ICOS-
ligand expression on the DCs (143a).
There are many intriguing reports that immature DCs suppress immunity fol-
lowing adoptive transfer into mice. Two recent examples are the transfer of antigen-
specific hyporesponsiveness by ICOS-ligand expressing and IL-10 producing
pulmonary DCs, in a model of airway allergy (143a), and by a subset of IL-
10 producing, CD4+ CD8− splenic DCs in a model of autoimmune experimental
allergic encephalitis (42). Likewise the control of CD25+Ts by antigen-presenting
cells in vivo remains to be investigated. This will be important because CD25+
Ts are responsible for protection against a number of autoimmune syndromes. In
conclusion, there is evidence that it would be worthwhile to pursue a role for DCs
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DISCUSSION: SOME QUESTIONS ABOUT TOLEROGENIC
DENDRITIC CELLS
What Mechanisms Underlie the Function of Dendritic Cells
in Inducing Tolerance?
The T cell is likely to be a major determinant in the tolerance outcome. In the
thymus engagement of the TCR on a newly generated single positive thymocyte
may initiate an apoptotic program involving the bim proapoptotic pathway (150).
In other words, antigen-presenting thymic DCs may not require a special capacity
to kill developing self-reactive thymocytes. Analogously, peripheral tolerance may
be the “default” pathway, again proceeding via bim (151) whenever T cells are
stimulated to grow in the absence of further stimuli from maturing DCs. DC mat-
uration is the critical switch that provides signals for effector T cell development
and memory, diverting T cells from apoptosis to protective immune function. For
example, maturation stimulates DCs to produce immune-enhancing cytokines like
IL-12 or IFN-α and to express high levels of membrane costimulatory molecules
that promote T cell survival and cytokine/cytolysin production.
A more active potential immunosuppressive pathway that needs to be eval-
uated in vivo involves DC production of tryptophan metabolites through the
action of indoleamine 2,3-dioxygenase (IDO) (Figure 1). IDO exists in DCs
within mouse (152) and human (152a) lymphoid tissues, and expression may
increase during inflammation (152a). IDO activity can be induced via IFN-γ
receptors, and this leads to T cell apoptosis in culture (152). IFN-γ receptors
(CD119) are markedly downregulated as the DC matures (152–154). The IDO-
catalyzed tryptophan metabolites are responsible for killing T cells, especially ac-
tivated T cells (155). Recently it was shown that CTLA-4Ig triggers B7 molecules
on DCs to induce IDO (155a).
More “active” roles may also need to be played if DCs prove to be important in
inducing tolerance via Tr1 and Ts cells. For example, DC production of IL-10 and
other immunosuppressive cytokines may be critical for the differentiation of Tr1.
IL-10 production could in turn be stimulated by products in an exposed epithelium
like the airway or intestine or by microbial products in the lumen. Alternatively,
some suppressor cells may be programmed to suppress when they are generated
in the thymus.
Even though tolerogenic DCs may not kill peripheral T cells directly, the DCs
nevertheless need to carry out several sets of activities (Figure 1). The first is the
capture and processing of self- and environmental antigens, including for presen-
tation on MHC class I products. Figure 1 diagrams a number of specializations
of DCs in antigen presentation, i.e., the formation of MHC-peptide complexes.
These specializations include distinct endocytic receptors, the efficacy in carry-
ing out the exogenous pathway for processing and presentation on MHC class I,
and the regulation of antigen processing during responses to maturation stimuli.
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These position DCs appropriately in the steady state for the capture of dying cells
and environmental proteins and for interaction with T cells in lymphoid tissues.
Distinct chemokine receptors can be expressed by DCs in different subsets (plas-
macytoid DCs express CXCR4; monocyte-derived DCs typically express CCR5),
locations (epithelial DCs express CCR6), and maturation states (mature DCs al-
ways express CCR7). Nonetheless, much needs to be learned about the origin of
DCs in the T cell areas of lymphoid organs and the control of DC traffic in the
steady state. Third, immature DCs can express adhesion molecules for T cells,
such as DC-SIGN or CD209, a lectin that binds ICAM-3 on resting T cells (156).
In the steady state, DCs in lymphoid organs also express significant amounts of
CD80 and CD86, but the role of these molecules in tolerance remains to be as-
certained. Likewise, many members of the TNF family can be expressed by DCs
(e.g., OX40L/CD134L, 4-1BBL/CD137L), but their expression in vivo needs ad-
ditional investigation. CD134L seems important for mesenteric lymph node DCs
to drive colitis-inducing T cells (156a). Many of these features of DCs can change
with maturation. The DCs then dampen expression of some properties and acquire
new functions, including the production of growth factors like IL-2 and thiols,
cytokines, and much higher levels of T cell interaction molecules like CD40,
CD86, and B7-DC, which allow DCs to play active roles in initiating immunity
(Figure 1).
Will Targeting to Dendritic Cells Lead to Tolerance with Low
Doses of Antigen?
As mentioned in Table 1, one of the enigmas in tolerance is how the immune
system remains tolerant to small amounts of most harmless proteins that are present
in the steady state, especially when DCs should be able to process and present
many of these self- and environmental proteins during DC maturation in response
to infection. In physiologic circumstances, DCs appear to be the predominant
cells that continually take up and process antigens for presentation to T cells.
Many of the markers used to identify DCs are in fact endocytic receptors that
could enhance antigen uptake. We mentioned above such molecules as DEC-205,
langerin, asialoglycoprotein receptor, BDCA-2, and DC-SIGN (Figure 1). Once
antigen is taken up, DCs seem particularly efficient at forming and exporting MHC
class II peptide complexes (32, 157, 158, 158a). For example, when a DC takes
up 105 I-E molecules from dying B cells, it forms several thousand MHC II/I-E
peptide complexes (84). Furthermore, DCs are proficient and perhaps unique in
processing nonreplicating antigens into peptides that are transported into the rough
endoplasmic reticulum by TAPs and presented on MHC class I products. This
exogenous pathway extends to dying cells, immune complexes, and ligands for
the DEC-205 receptor (Figure 1).
Uptake and processing mechanisms are continuously active in the immature
DCs located within lymphoid tissues in the steady state. These functions are further
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up proteins and dying cells continuously in the steady state (25, 93, 94). Two
intriguing new studies indicate that a subset of CD16+monocytes are specialized
to differentiate into DCs that move from tissues into lymph (158a), and that DCs
can upregulate the CCR7 lymph node homing receptor following uptake of dying
cells (158c), with uptake of dying autologous cells being a steady state function of
DCs (25)(93). To date, only DCs in lymphoid organs have been shown to process
antigens in the steady state, and it is possible that DCs in peripheral tissues need
to receive additional stimuli to present the antigens they have captured.
Other cell types may not gain access to significant amounts of self- and envi-
ronmental antigens in the steady state or may not process them to MHC class I and
class II peptide complexes with the same efficiency as DCs. However, non-DCs
may present MHC-peptide complexes when animals are given large amounts of
antigen, especially if the antigen is given as preprocessed peptides, as is the case in
several reports on the induction of peripheral tolerance. The underlying tolerance
mechanism induced by non-DCs may be anergy, which is a reversible form of
tolerance. Evidence for anergy induction through non-DCs was recently obtained
with NKT cells from mice treated with high doses of a glycolipid,α-galactosyl
ceramide (10). This synthetic drug is presented on CD1d molecules to invariant
TCRs on NKT cells. If the glycolipid was selectively targeted to DCs, a prolonged
effector type of NKT response was induced, but if the drug was allowed to access
non-DCs, the latter induced dominant anergy in the NKT cells.
How Might Tolerogenic Dendritic Cells Contribute to Disease
and Therapy?
If DCs continually sample self to induce peripheral tolerance, then chronic ac-
tivation would vitiate their role in bringing about T cell deletion. In the autoim-
mune disease systemic lupus erythematosus evidence has been obtained that blood
monocytes express features of stimulatory DCs (159) owing to increases in serum
IFN-α (159). It is proposed that the more stimulatory DCs in lupus may present
self-nucleoprotein complexes, resulting in autoimmunity rather than tolerance.
Similarly, when CD40L is expressed as a transgene in mouse epidermis under
the control of the K14 promoter, Langerhans cells are chronically mature, and
systemic autoimmunity develops (160).
It is evident that many tissue antigens do not induce tolerance but are ignored
by the immune system (161, 162). These ignored antigens would then have the
potential to induce autoimmunity. Ignorance in cell biological terms may mean
that an antigen is insufficiently processed and presented by DCs in the steady state.
For example, when antigens from isletβ cells are presented by lymph node DCs in
the steady state, a low level of antigen expression in the islets is associated with poor
antigen presentation in the lymph node (163). During infection, ignored proteins
might be processed by proteases released from microorganisms, leukocytes, or
dying leukocytes. These peptides could then be presented by DCs that are maturing
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In chronic infectious diseases, the tolerogenic role of DCs might be exploited by
the pathogen to reduce the protective immune response. It has been hypothesized
that this situation may occur with persistent microbes that are taken up by DCs
without maturing them (95). The DCs may then unwittingly induce tolerance,
either deleting reactive T cells or inducing regulatory cells. HIV-1 may be such an
example because it is produced in high amounts in the absence of antiretroviral
drugs, and DCs in the steady state express receptors to capture virus.
In transplantation DC maturation in both donor and recipient is likely to accom-
pany the preparation and engraftment of organ allografts (164). Whereas a block
in DC maturation should reduce the initial sensitization to the transplant, at the
levels of the transplant donor (the direct pathway whereby alloMHC and minor
histocompatibility antigens are presented by DCs from the allograft) and recipient
(the indirect pathway whereby recipient DCs present peptides from alloMHC and
minor histocompatibility antigens from the graft), it is additionally possible that a
block in maturation will enhance the induction of antigen-specific tolerance.
Tolerance is considered to be a potential obstacle to tumor immunotherapy
because the persistent tumor cells might be regarded as self. This needs to be
looked at with the new tools that are available to study specific antitumor immune
responses. In the case of multiple myeloma one can use DCs to present whole tumor
cells to T cells from the tumor environment. When this is done, the DCs induce
strong responses in CD8+ T cells from patients with progressive tumors (165),
implying that if there is tolerance to myeloma, it is far from complete. Possibly the
antiapoptotic processes that are vital to tumorigenesis represent the immunologic
Achilles heel of tumor cells. If DCs are unable in the steady state to capture
and present cancer cells in a tolerogenic mode, the antitumor T cell repertoire
may not be silenced. Instead T cells would be amenable to DC-mediated active
immunotherapy.
TheAnnual Review of Immunologyis online at http://immunol.annualreviews.org
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